CPMVOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Mosaic ImmunoEngineering Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.33+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $2.41M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q1 FY2011 Ended Aug 31, 2010 | Oct 13, 2010 | After market close | – | – | – |
Press releases
Announcements Mosaic ImmunoEngineering filed with the SEC
Agrees to Acquire Clinical Necroptosis Cancer Therapy Assets from Oncotelic Therapeutics, Inc.
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
of Exclusive Technology License Agreement with Case Western Reserve University
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K